Publications by authors named "G A FROMM"
Article Synopsis
- Lipid nanoparticle (LNP)-encapsulated mRNA can produce various therapeutic proteins in vivo, facilitating the creation of personalized cancer vaccines and enhancing drug delivery methods.
- The study demonstrated that mRNA/LNP formulations of specific proteins substantially increased their production and presence in tumors compared to traditional recombinant proteins, with up to 140-fold improvement in exposure over 96 hours.
- Additionally, these formulations stimulated a stronger immune response, prolonged survival in cancer models, and showed improved efficacy when combined with existing treatments, suggesting potential for better patient outcomes.
Article Synopsis
- Immunotherapy using PD-(L)1 blockade is common for treating non-small cell lung cancer (NSCLC), but over 60% of initial responders develop acquired resistance.
- Research indicates that this resistance is linked to differences in inflammation and interferon (IFN) signaling, with relapsed tumors showing varied expressions of IFNγ response genes.
- Understanding the altered IFN response in these tumors may help develop new strategies to overcome resistance and improve treatment effectiveness.
New treatments are needed for relapsed and refractory CD30-expressing lymphomas. We developed a novel anti-CD30 chimeric antigen receptor (CAR), designated 5F11-28Z. Safety and feasibility of 5F11-28Z-transduced T cells (5F11-Ts) were evaluated in a phase 1 dose escalation clinical trial.
View Article and Find Full Text PDFArticle Synopsis
- The extracellular domain of tumor necrosis factor receptors (TNFR) must form a homotrimer structure to activate signaling through their cytoplasmic domains, which can be triggered by both natural TNF ligands and synthetic agonists.
- Research suggests that synthetic agonists targeting various TNF receptors could enhance immune responses in cancer and infectious disease, but success in animal studies has not translated effectively to human trials.
- Clinical concerns such as liver toxicity and adverse effects from overstimulation of TNF receptors have limited the development of these therapies, prompting further studies to understand the mechanisms behind TNFR activation and help optimize therapeutic strategies.
Article Synopsis
- Despite extensive trials using PD-1/L1 inhibitors for treating certain resistant solid tumors, significant survival benefits remain elusive, especially in myelosuppressive environments.
- Achieving effective anti-tumor immunity might require a multifaceted approach that includes immune cell activation, myeloid repolarization, and targeting specific signals that prevent immune cells from attacking tumors.
- Recent insights suggest that LIGHT, a tumor necrosis factor ligand, offers potential therapeutic benefits by activating myeloid cells and enhancing T/NK cell responses, along with promoting changes in the tumor microenvironment that can foster better immune responses.